These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 4707801

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The role of the federal government in the development of narcotic antagonists.
    Green AI.
    Adv Biochem Psychopharmacol; 1973; 8(0):576-7. PubMed ID: 4795123
    [No Abstract] [Full Text] [Related]

  • 5. Methadone treatment versus therapeutic communities: preliminary results of a randomized study in progress.
    Bale RN, Van Stone WW, Kuldau JM, Engelsing TM, Zarcone VP.
    Proc Natl Conf Methadone Treat; 1973; 2():1027-34. PubMed ID: 4808243
    [No Abstract] [Full Text] [Related]

  • 6. Treating today's heroin user.
    Raskin HA.
    Am Fam Physician; 1973 Aug; 8(2):77-80. PubMed ID: 4720393
    [No Abstract] [Full Text] [Related]

  • 7. [Pharmacologic aspects of the treatment of drug addiction due to morphine-like substances].
    Babaian EA, Bulaev VM.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1989 Aug; 89(1):134-9. PubMed ID: 2566216
    [No Abstract] [Full Text] [Related]

  • 8. Addiction and the community. (Narcotic substitution therapy).
    Taylor WJ, Chambers CD, Bowling CE.
    Int J Clin Pharmacol; 1972 Apr; 6(1):28-39. PubMed ID: 4625924
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of chemical dependency of the morphine type.
    Maslansky RA.
    Minn Med; 1973 Mar; 56(3):205-6. PubMed ID: 4688364
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Initial experiences in an experimental clinic for the treatment of juvenile drug addicts].
    Springer A, Kremser M.
    Wien Z Nervenheilkd Grenzgeb; 1973 Mar; 31(3):241-50. PubMed ID: 4273129
    [No Abstract] [Full Text] [Related]

  • 14. Blockade with methadone, cyclazocine, and naloxone.
    Freedman AM, Zaks A, Resnick R, Fink M.
    Int J Addict; 1970 Sep; 5(3):507-15. PubMed ID: 5524385
    [No Abstract] [Full Text] [Related]

  • 15. An examination of repeated heroin abuse by patients maintained on methadone.
    Bayer R, Kremen E.
    Proc Natl Conf Methadone Treat; 1973 Sep; 2():1093-7. PubMed ID: 4808254
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Follow-up evaluations of inpatient detoxification patients.
    Strelinger RW, Angle HV, Crawford J, Yaffe GJ, Parwatikar S.
    Proc Natl Conf Methadone Treat; 1973 Sep; 1():464-70. PubMed ID: 4808186
    [No Abstract] [Full Text] [Related]

  • 18. Treatment for drug abusers in the United States.
    Nightingale SL.
    Addict Dis; 1977 Sep; 3(1):11-20. PubMed ID: 930684
    [No Abstract] [Full Text] [Related]

  • 19. Psychological and sociological factors involved in treatment planning for drug abusers.
    Margolis CG.
    Am J Pharm Sci Support Public Health; 1971 Sep; 143(2):45-50. PubMed ID: 4936232
    [No Abstract] [Full Text] [Related]

  • 20. Drug abuse: models of treatment and their consequences.
    Lief VF.
    Int Pharmacopsychiatry; 1972 Sep; 7(1-4):7-21. PubMed ID: 4619399
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.